Monoclonal Antibody to Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 (MCL1)

EAT; MCL1L; MCL1S; BCL2L3; TM; Myeloid Cell Leukemia Sequence 1, Bcl2 Related; Bcl-2-like protein 3; Bcl-2-related protein EAT/mcl1; mcl1/EAT

SPECIFITY

The antibody is a mouse monoclonal antibody raised against MCL1. It has been selected for its ability to recognize MCL1 in immunohistochemical staining and western blotting.

USAGE

Western blotting: 0.2-2µg/mL;1:500-5000
Immunohistochemistry: 5-20µg/mL;1:50-200
Immunocytochemistry: 5-20µg/mL;1:50-200
Optimal working dilutions must be determined by end user.

STORAGE

Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.

STABILITY

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Cancers Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075
ACTA NEUROPATHOLOGICA COMMUNICATIONS Restoration of miR-193a expression is tumor-suppressive in MYC amplified Group 3 medulloblastoma Pubmed: 32410663
Cancers (Basel) BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760